Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Excision Biotherapeutics

Request full access

Developing CRISPR-based therapies intended to cure viral infectious diseases

Watertown, United StatesFounded 2015Biotech & Life Sciences

About Excision Biotherapeutics

Excision BioTherapeutics is a biotechnology startup that operates in the field of gene therapy. The company's primary focus is on developing a functional cure for HIV, a feat they have already achieved in animals. They use a revolutionary gene-editing technology called CRISPR, which they have licensed from the Doudna Lab at UC Berkeley and the Khalili Lab at Temple University.

CRISPR, which stands for Clustered Regularly Interspaced Short Palindromic Repeats, is a technology that allows scientists to edit genes within organisms. In simple terms, it's like a pair of molecular scissors that can cut out harmful genes and replace them with healthy ones. Excision BioTherapeutics uses this technology to target and remove the HIV genome from the body, thereby curing the disease.

The company's business model is based on the development and commercialization of its gene therapies. Once a therapy is developed, it can be sold to healthcare providers who administer it to patients. The company's primary market is individuals living with HIV, but the technology has the potential to be used to cure other infectious diseases as well.

Excision BioTherapeutics generates revenue by selling its gene therapies. The therapies require only a one-time edit to remove the viral genome permanently, which could make them a cost-effective solution for healthcare providers and patients.

In conclusion, Excision BioTherapeutics is a pioneering biotech startup that is using cutting-edge gene-editing technology to develop a functional cure for HIV. The company's innovative approach has the potential to revolutionize the treatment of infectious diseases and bring much-needed therapies to patients around the world.

Source: Dealroom company data

At a glance

Status
Operational
Employees
24
Open positions
None listed
Dealroom signal
30.0/100
Industry
Health
Sub-industry
BioTechnology
Sector
Intellectual Property, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

8 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
GRANTOther financing Sep 2022 $6.9M — California Institute for Regenerative Medicine ↗
EARLY VCOther financing Feb 2021 $60M $240M Norwest Venture Partners · Olive Tree Capital · Artis Ventures · Cota Capital —
Showing the latest 2 of 8 recorded eventsBook a demo for the full funding history →

Growth signals

Excision Biotherapeutics website traffic

Latest recorded traffic for Excision Biotherapeutics is 130 monthly website visits, down 98% over the last three months. Excision Biotherapeutics's team declined 40% over the past year.

Latest monthly visits130 3-month web change-98% 1-year team growth-40%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Excision Biotherapeutics in the Watertown ecosystem

Live from Dealroom

The Excision Biotherapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

18 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed7 investors entered at this stage

  • Oakhouse Partners
  • Artis Ventures
  • Gaingels
  • Alumni Ventures
  • Benjamin Kong
  • Bioverge
  • California Institute for Regenerative Medicine

Series A9 investors entered at this stage

Series B and later1 investor entered at this stage

  • Ben Franklin Technology Partners of Southeastern Pennsylvania

Other known investors1 additional known investor

  • Stanford University
Team profiled 14 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 3 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
4 countries with
team presence
🇺🇸 United States72.7%
🇦🇪 United Arab Emirates9.1%
🇩🇪 Germany9.1%
🇨🇦 Canada9.1%
4 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Excision Biotherapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Excision Biotherapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.